ESHAP salvage therapy for refractory and relapsed non-Hodgkin's lymphoma: A single center experience

Korean Journal of Internal Medicine

Volumn 21, Issue 3, 2006, Pages 159-164

  Park, Sang Hyoung ^a   Kim, Shin ^a   Ko, Ok Bae ^a   Koo, Ja Eun ^a   Lee, Danbi ^a   Jeong, Yong Pil ^a   Huh, Jooryung ^a   Kim, Sung Bae ^a   Kim, Sang We ^a   Lee, Jae Lyun ^a   Suh, Cheolwon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

ESHAP regimen; Lymphoma; Non Hodgkin; Salvage therapy

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; KOREA; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; SALVAGE THERAPY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UREMIA;

EID: 37849188578     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2006.21.3.159     Document Type: Article

References (22)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023-1030, 1993
2. Fisher RI, Miller TP, Dana BW, Jones SE, Dahlberg S, Coltman CA Jr. Southwest oncology group clinical trials for intermediate and high grade non-Hodgkin's lymphoma. Semin Hematol 24(2 Suppl 1):21-25, 1987
3. Carde P, Meerwaldt JH, van Glabbeke M, Somers R, Monconduit M, Thomas J, de Wolf-Peeters C, de Pauw B, Tanguy A, Kluin-Nelemans JC. Superiority of second over first generation chemotherapy in a randomized trial for stage III-IV intermediate and high grade non-Hodgkin's lymphoma: the 1980-1985 EORTC trial. Ann Oncol 2:431-435, 1991
4. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
5. Cabanillas F. Experience with salvage regimens at M.D. Anderson Hospital Ann Oncol 2(Suppl 1):31-32, 1991
6. Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60:693-697, 1982
7. Cabanillas F, Hagemeister FB, McLaughlin P, Velasquez WS, Riggs S, Fuller L, Smith T. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5:407-412, 1987
8. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood 71:117-122, 1988
9. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 11:1573-1582, 1993
10. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat F, Goldstone AH, Gorin NC, Flesh M. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high grade non-Hodgkin's lymphoma. N Engl J Med 316:1493-1498, 1987
11. Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F. ESHAP: an effective chemotherapy regimen in refractory and relapsing lymphoma: a four-year follow-up study. J Clin Oncol 12:1169-1176, 1994
12. Ezzat A, Khalifa F, Berry J, Khan B, Raja MA, Abdel-Warith A. ESHAP: an effective treatment in selected patients with relapsed non-Hodgkin's lymphoma. Ann Oncol 5:453-456, 1994
13. Wang WS, Chiou TJ, Liu JH, Fan FS, Yen CC, Tung SL, Chen PM. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience. Jpn J Clin Oncol 29:33-37, 1999
14. Bergerat JP, Dreawinko B, Corry P, Barlogie B, Ho DH. Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-b-D-arabinosylcytosine. Cancer Res 41:25-30, 1981
15. Choi CW, Paek CW, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS. ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma. J Korean Med Sci 17:621-624, 2002
16. Johnson PW, Sweetenham JW, McCallum P, Norton AJ, Rohartiner AZ, Lister TA. E-SHAP: inadequate treatment for poor-prognosis recurrent lymphoma. Ann Oncol 4:63-67, 1993
17. Coiffier B. Treatment of aggressive non-Hodgkin's lymphoma. Semin Oncol 26:12-20, 1999
18. Appelbaum RF, Herzig GP, Ziegler JL, Graw RG, Levine AS, Deisseroth AB. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 52:85-95, 1978
19. Ho AD, del Valle FD, Ruckle H, Schwammborn J, Schlimok G, Hiddemann W, Meusers P, Thiel E, Dorken B, Hunstein W. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. Cancer 64:1388-1392, 1989
20. Rodriguez-Monge EJ, Cabanillas F. Long-term follow-up of platinum-based lymphoma salvage regimens: the M.D. Anderson Cancer Center experience. Hematol Oncol Clin North Am 11:937-947, 1997
21. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734-1741, 1995
22. Gisselbrecht C, Mounier N. Improving second-line therapy in aggressive non-Hodgkin's lymphoma. Semin Oncol 31(1 Suppl 2):12-16, 2004